AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22419702
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical doses)
Trial: 22419702
Drug: Metformin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (in obese women)
Trial: 22419702
Drug: Metformin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (in nonobese women)
Trial: 22419702
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus standard infertility treatment
Trial: 19669678
Drug: Ranibizumab (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (monthly administration)
Trial: 16192479
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg every 12 hours)
Trial: 10823763
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of prophylaxis (n=355)
Trial: 8651713
Drug: 8% glycolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% glycolic acid cream
Trial: 8651713
Drug: 8% L-lactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% L-lactic acid cream
Trial: 1995051
Drug: Lignocaine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 1.5 mg/kg intravenously prior to induction
Trial: 31722941
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 540,000 IU cholecalciferol followed by 4000 IU daily for 90 days
Trial: 22726885
Drug: Prothrombin complex
RxNorm normalized name: prothrombin complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothrombin complex concentrate (PCC) administered at a dose of ≥20 UI/kg with vitamin K
Trial: 22726885
Drug: Prothrombin complex
RxNorm normalized name: prothrombin complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothrombin complex concentrate (PCC) administered at a dose of >20 UI/kg
Trial: 22726885
Drug: Prothrombin complex
RxNorm normalized name: prothrombin complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothrombin complex concentrate (PCC) administration
Trial: 16889639
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone pulse (IVGC)
Trial: 16889639
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (OGC)
Trial: 12519218
Drug: AOC7 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOC7 (1000 mg amoxicillin, 20 mg omeprazole, and 500 mg clarithromycin twice daily for 7 days)
Trial: 12519218
Drug: FOT4 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOT4 (200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 4 days)
Trial: 12519218
Drug: FOT7 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOT7 (200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 7 days)
Trial: 8892160
Drug: Surgery after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery after failed behavioral treatment
Trial: 31767474
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with 66 Gy (24x2.75 Gy) and low dose Cisplatin +/− Cetuximab
Trial: 31767474
Drug: Post-treatment PET-metrics
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment PET-metrics (SUVmax, SUVmean, MTV, TLG)
Trial: 28003538
Drug: Whey Protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey Protein supplementation (0, 20, 40, or 60 g WP/d)
Trial: 26030325
Drug: Add-on alirocumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on alirocumab 75 mg every 2 weeks (Q2W)
Trial: 26030325
Drug: Add-on ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Add-on ezetimibe 10 mg/d
Trial: 26030325
Drug: Switching atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching atorvastatin 40 mg to rosuvastatin 40 mg
Trial: 20354035
Drug: sivelestat 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sivelestat 0.2 mg/kg/h
Trial: 10706930
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (long‐cycle transdermal 17‐beta‐estradiol 50 microg/24 hour for 3 months with sequential medroxy‐progesterone acetate for 14 days)
Trial: 8931030
Drug: Twice-weekly structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly structured exercise program
Trial: 6430329
Drug: Amino acids
RxNorm normalized name: Amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acids (L‐cysteine, glycine, DL‐threonine)
Trial: 24176943
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of antiretroviral therapy (ART) during TB treatment
Trial: 24176943
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of antiretroviral therapy (ART) during TB treatment
Trial: 20578825
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy for one year
Trial: 12439223
Drug: bupropion (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupropion (300 mg/day for 10 weeks)
Trial: 9579500
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (4 microg/kg) with glucose-free solution
Trial: 9579500
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 2% glucose with clonidine
Trial: 7650232
Drug: Venlafaxine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (50 mg every 8 hours for 10 days)
Trial: 7650232
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg single dose on day 5)
Trial: 2669089
Drug: Dexfenfluramine 15
RxNorm normalized name: dexfenfluramine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine 15 mg b.d.
Trial: 975730
Drug: Cefamandole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (1 gm intravenous)
Trial: 975730
Drug: Cephalothin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin (1 gm intravenous)
Trial: 975730
Drug: Cefamandole and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole and Cephalothin (both drugs)
Trial: 27996097
Drug: Infection-preventive technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infection-preventive technique including povidone-iodine, double gloving, meticulous aseptic/antiseptic measures, and antibiotic prophylaxis.
Trial: 24139127
Drug: Higenamine-based dietary
RxNorm normalized name: Higenamine
DrugBank: Higenamine (DB12779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higenamine-based dietary supplement (including caffeine 270 mg and yohimbe bark extract)
Trial: 9427706
Drug: Desmopressin (DDAVP)
RxNorm normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (DDAVP) infusion at stepwise doses of 0.7, 7.0, and 70 ng/min
Trial: 9427706
Drug: Constant-rate DDAVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant-rate DDAVP infusion at 70 ng/min for 20 minutes
Trial: 9427706
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) infusion at doses of 0.5, 2.5, and 10 micrograms/min
Trial: 9427706
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (dominant arm) during constant-rate DDAVP infusion
Trial: 27112096
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of treatment by a specialist physiotherapist
Trial: 7646915
Drug: Hormonal or
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal or chemotherapy
Trial: 7646915
Drug: Radio/chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radio/chemotherapy
Trial: 346356
Drug: Pindolol 5
RxNorm normalized name: pindolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 5 mg (single oral dose)
Trial: 346356
Drug: Salbutamol (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (conventional therapeutic dose by inhalation)
Trial: 28787738
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (weight loss treatment)
Trial: 23600983
Drug: Cevimeline 30
RxNorm normalized name: Cevimeline 30mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cevimeline 30 mg three times a day for four weeks
Trial: 23600983
Drug: Pilocarpine 5
RxNorm normalized name: PILOCARPINE 5MG/UNT OPH,CRC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine 5 mg three times a day for four weeks
Trial: 19405969
Drug: High Intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Intensity Treatment (HIT)
Trial: 19405969
Drug: Low Intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Intensity Treatment (LIT)
Trial: 16931871
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine pre-treatment
Trial: 15303766
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg isosorbide dinitrate (sustained-release)
Trial: 31970477
Drug: Minodronate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minodronate (50 mg/4 weeks) plus alfacalcidol (1 μg/day)
Trial: 31970477
Drug: Alfacalcidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1 μg/day)
Trial: 23060624
Drug: NVA237 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 50 μg
Trial: 18666494
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active bleaching agents (including 10% carbamide peroxide with potassium nitrate)
Trial: 16129870
Drug: Patient decision
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient decision aid (self-administered booklet and audiotape tailored to personal stroke risk profile)
Trial: 10786195
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m2 on 5 consecutive days every 3 weeks
Trial: 10786195
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of topotecan 0.3 to 0.5 mg/m2
Trial: 10786195
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m2/day for 5 consecutive days every 21 days
Trial: 1997045
Drug: Clonidine 7
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 7 micrograms kg‐1 i.v. infusion over 120 min
Trial: 6386760
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy with misonidazole (12 g/m2 daily in 1.2 g/m2 fractions)
Trial: 19411388
Drug: naproxcinod 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxcinod 750 mg once daily (qd)
Trial: 19411388
Drug: naproxcinod 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxcinod 750 mg twice daily (bid)
Trial: 19411388
Drug: naproxcinod 1125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxcinod 1125 mg bid
Trial: 14693981
Drug: Troglitazone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (200 mg for 12 weeks)
Trial: 9852438
Drug: Blue filter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue filter treatment (flash stimulation with a blue filter during occlusion of the better eye for one hour daily)
Trial: 9852438
Drug: Blue filter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue filter treatment
Trial: 9852438
Drug: Classical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical treatment (full time total occlusion by patch)
Trial: 7989814
Drug: Perioperative, high-dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative, high-dosage antibiotic administration
Trial: 7989814
Drug: Existing prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing prophylactic regimen with longer intervals and postoperative antibiotics for 7 to 10 days
Trial: 3802604
Drug: Sublingual nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual nifedipine 10 mg
Trial: 2690788
Drug: Oral captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral captopril 50 mg
Trial: 26439038
Drug: Progesterone vaginal
RxNorm normalized name: progesterone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone vaginal suppositories (400 mg, 200 mg 2 times per day) + Alpha Lipoic Acid (ALA) (600 mg, 300 mg 2 times per day)
Trial: 26439038
Drug: Progesterone vaginal
RxNorm normalized name: progesterone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone vaginal suppositories (400 mg, 200 mg 2 times per day)
Trial: 21070328
Drug: IPI implants
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IPI implants
Trial: 21070328
Drug: I‐Plant implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I‐Plant implants
Trial: 21070328
Drug: Both implant
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both implant systems (IPI and I‐Plant)
Trial: 21070328
Drug: Transitional implants
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transitional implants with good primary stability
Trial: 21070328
Drug: Gender, kind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender, kind of superstructure, location of the implant, tooth status of the opposing jaw, immediate prosthetic superstructure
Trial: 17273661
Drug: Thalidomide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (300 mg daily for 30 days)
Trial: 17273661
Drug: Pentoxifylline (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1.2 g daily for 30 days)
Trial: 9534995
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose at 1 year of age
Trial: 7723004
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of assessment measures
Trial: 2845707
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) 5000 anti-XaU injected every 24 hours
Trial: 2845707
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH) 5000 IU injected every 12 hours
Trial: 30366741
Drug: 1:1.5 carbohydrate‐protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1.5 carbohydrate‐protein supplement (16g CHO/25g PRO) pre-training (PRE)
Trial: 30366741
Drug: 1:1.5 carbohydrate‐protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1.5 carbohydrate‐protein supplement (16g CHO/25g PRO) post-training (POST)
Trial: 30366741
Drug: No supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplement (CON)
Trial: 29468530
Drug: Biomarker-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-guided therapy using NT-proBNP
Trial: 24841833
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 μg once daily via HandiHaler
Trial: 21964557
Drug: Repetitive leftward
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive leftward optokinetic stimulation (OKS) with smooth pursuit eye movements as therapy.
Trial: 21964557
Drug: Visual scanning
RxNorm normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual scanning therapy.
Trial: 17559376
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion for 12 hours (SOM1)
Trial: 17559376
Drug: Gabexate infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabexate infusion for 12 hours (GAB1)
Trial: 17559376
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion for less than 12 hours (SOM2)
Trial: 17559376
Drug: Gabexate infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabexate infusion for less than 12 hours (GAB2)
Trial: 10597956
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplement (2.5 mg or 1.0 mg)
Trial: 8598594
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (one of four regimens: streptokinase with subcutaneous heparin; streptokinase with intravenous heparin; streptokinase plus alteplase with intravenous heparin; accelerated alteplase with intravenous heparin)
Trial: 6113192
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg tds and 400 mg nocte
Trial: 31126541
Drug: Salix extract
RxNorm normalized name: SALIX
DrugBank: Willow bark (DB14691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salix extract (400 mg daily)
Trial: 31126541
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (750 mg daily)
Trial: 25052890
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of folic acid added to ADM for 12 weeks
Trial: 23171320
Drug: IFCR‐L (Intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFCR‐L (Intermittent fasting combined with calorie restriction and liquid diet)
Trial: 23171320
Drug: IFCR‐L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFCR‐L
Trial: 16304073
Drug: Enoxaparin (consistent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (consistent therapy)
Trial: 16304073
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (consistent therapy)
Trial: 11967499
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus medroxyprogesterone acetate (MPA) 2.5 mg
Trial: 2654254
Drug: Ketotifen (Zaditen;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (Zaditen; Sandoz Pharmaceuticals, Basel, Switzerland)
Trial: 26028120
Drug: Continued methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued methadone treatment
Trial: 23447518
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (rhGH) therapy
Trial: 19133062
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of diclofenac (30 mg total from two tapes)
Trial: 19133062
Drug: Oral application
RxNorm normalized name: Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral application of diclofenac (37.5 mg capsule)
Trial: 16400897
Drug: Budesonide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (400 microg daily)
Trial: 12468570
Drug: Ramipril (escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (escalated to 10 mg/d)
Trial: 12468570
Drug: Losartan (escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (escalated to 100 mg/d)
Trial: 326261
Drug: Piprozoline (Problin)
RxNorm normalized name: piprozoline
DrugBank: Piprozolin (DB13202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piprozoline (Problin) therapy
Trial: 22582872
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg Loperamide (LOP)
Trial: 22582872
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg Loperamide (LOP) + 125 mg Simethicone (SIM)